BridgeBio Pharma, Inc. BBIO
79.24 USD +1.31 (+1.68%)
Nov 10, 2026, 1:58 PM EST
76.60 Day range 79.83
62.06 52-week range 93.42
- YTD
- +3.60%
- 1 year
- +26.16%
BBIO revenue history
Revenue is income from the company’s ordinary business activities.
502,076,000 USD
FY 2025 · Period ended
Coverage: complete. Values in USD; not inflation adjusted.
Reporting currency is USD by the source’s USD conversion factor of 1; the source does not name the currency.
Scroll the table to see all values →
| Fiscal period | Period end | Revenue | YoY change | YoY % |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | 502,076,000 | 280,174,000 | 126.26% |
| FY 2024 | 2024-12-31 | 221,902,000 | 212,599,000 | 2285.27% |
| FY 2023 | 2023-12-31 | 9,303,000 | -68,345,000 | -88.02% |
| FY 2022 | 2022-12-31 | 77,648,000 | 7,932,000 | 11.38% |
| FY 2021 | 2021-12-31 | 69,716,000 | 61,467,000 | 745.14% |
| FY 2020 | 2020-12-31 | 8,249,000 | -32,311,000 | -79.66% |
| FY 2019 | 2019-12-31 | 40,560,000 | 40,560,000 | Not meaningful |
| FY 2018 | 2018-12-31 | 0 | 0 | Not meaningful |
| FY 2017 | 2017-12-31 | 0 | Not available | Not available |
Percentage growth is shown only when the same fiscal period one year earlier has a positive value. Missing periods are not estimated.
Company-reported financial statements. Retrieved 2026-05-08T14:24:23.000Z. Retrieval time is not a report date.
Open full statementsUse Add to watchlist above to save this stock.